酪氨酸激酶抑制剂时代,慢性髓细胞白血病的热点话题

[1]	Hehlmann R.Efficacy and safety of imatinib in CML over 10 years[J].J Clin Oncol,2014,32:abstr 7021.
[2]	Jiang Q,Xu LP,Liu DH,et al.Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia[J].Leukemia,2013,27:2410-2413.
[3]	Hughes T,White D.Which TKI? An embarrassment of riches for chronic myeloid leukemia patients[J].Hematology Am Soc Hematol Educ Program,2013,2013:168-175.
[4]	Baccarani M,Deininger MW,Rosti G,et al.European Leukemia Net recommendations for the management of chronic myeloid leukemia:2013[J].Blood,2013,122:872-884.
[5]	Quintás-Cardama A,Cortes JE,O'Brien S,et al.Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia[J].Cancer,2009,115:2912-2921.
[6]	Branford S,Roberts N,David T,et al.Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months[J].Blood,2013,122:abstr 254.
[7]	Jabbour E,Kantarjian H,O'Brien S,et al.The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors[J].Blood,2011,118:4541-4546.
[8]	DeAngelo DJ,Chen L,Guerin A,et al.Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure:a chart review analysis[J].Clin Lymphoma Myeloma Leuk,2014,14:245-251.
[9]	Steegmann JL,Cervantes F,le Coutre P,et al.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia[J].Leuk Lymphoma,2012,53:2351-2361.
[10]	Efficace F,Baccarani M,Breccia M,et al.Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population[J].Blood,2011,118:4554-4560.
[11]	Efficace F,Baccarani M,Breccia M,et al.Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib[J].Leukemia,2013,27:1511-1519.
[12]	Mo XD,Jiang Q,Xu LP,et al.Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib[J].Bone marrow transplant,2014,49:576-580.
[13]	Dusetzina SB,Winn AN,Abel GA,et al.Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia[J].J Clin Oncol,2014,32:306-311.
[14]	Experts in Chronic Myeloid Leukemia.The price of drugs for chronic myeloid leukemia is a reflection of the unsustainable prices of cancer drugs:from the perspective of a large group of CML experts[J].Blood,2013,121:4439-4442.
[15]	Francois X,Delphine R,Joelle G,et al.Long term follow-up after imatinib cessation for patents in deep molecular response:the update result of the STIM1 study[J].Blood,2013,122:515-522.
[16]	Rousselot P,Charbonnier A,Cony-Makhoul P,et al.Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease[J].J Clin Oncol,2014,32:424-430.
[17]	Huang X.Guideline for the diagnosis and management in the disease monitoring of patients with chronic myeloid leukemia in China (2014)[J].Chin J Hematol,2014,35:781-784.
[18]	Sinclair A,Latif AL,Holyoake TL.Targeting survival pathways in chronic myeloid leukemia stem cells[J].Br J Pharmacol,2013,169:1693-1707.
[19]	Zabriskie MS,Eide CA,Tantravahi SK,et al.BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia[J].Cancer Cell,2014,26:428-442.
[20]	Jabbour E,Kantarjian H.Chronic myeloid leukemia:2014 update on diagnosis,monitoring,and management[J].Am J Hematol,2014,89:547-556.